Epelsiban
Alternative Names: 557296; GSK557296Latest Information Update: 02 Jul 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class
- Mechanism of Action Oxytocin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Infertility; Premature ejaculation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Infertility(In volunteers) in USA (PO, Tablet)
- 13 Jun 2016 GlaxoSmithKline terminates phase I trial in Infertility (In volunteers) in USA (IV) (NCT02213029)
- 06 Jun 2016 GlaxoSmithKline plans a phase II trial in Adenomyosis in USA (NCT02794467)